Albertsons Companies, Inc. (ACI) reported $18.56 billion in revenue for the quarter ended November 2023, representing a year-over-year increase of 2.2%. EPS of $0.79 for the same period compares to $0.87 a year ago.The reported revenue represents a surprise of +1.56% over the Zacks Consensus Estimate of $18.27 billion. With the consensus EPS estimate being $0.66, the EPS surprise was +19.70%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they comp ...

Shares of Albertsons Companies Inc. ACI, -0.22% dropped 0.7% in premarket trading Tuesday, after the grocery-store chain reported fiscal third-quarter profit and sales that exceeded expectations but saw a drop in gross margins. Albertsons, which is in the process of being acquired by Kroger Co. KR, -0.17%, said net income for the quarter to Dec. 2 was $361.4 million, or 62 cents a share, after income of $375.5 million, or 20 cents a share, in the year-ago period. Excluding nonrecurring items, adjusted earn ...

Financial Performance - Net sales for the 12 weeks ended December 2, 2023, were $18,557.3 million, an increase from $18,154.9 million for the same period in 2022, representing a growth of 2.2%[9] - Gross margin for the 12 weeks ended December 2, 2023, was $5,197.3 million, compared to $5,121.7 million in the prior year, reflecting an increase of 1.5%[9] - Operating income for the 12 weeks ended December 2, 2023, was $566.1 million, a decrease from $582.4 million in the same period last year, indicating a decline of 2.2%[9] - Net income for the 12 weeks ended December 2, 2023, was $361.4 million, down from $375.5 million in the prior year, representing a decrease of 3.5%[9] - Basic net income per Class A common share for the 12 weeks ended December 2, 2023, was $0.63, compared to $0.20 in the same period last year[9] Assets and Liabilities - Total assets as of December 2, 2023, were $26,496.5 million, an increase from $26,168.2 million as of February 25, 2023[6] - Total liabilities as of December 2, 2023, were $22,019.3 million, compared to $21,200.5 million as of February 25, 2023, reflecting an increase of 3.8%[6] - Total stockholders' equity as of December 2, 2023, was $2,527.3 million, an increase from $2,216.6 million[15] - The company had $4.5 million in restricted cash as of December 2, 2023, down from $8.0 million as of February 25, 2023[22] Cash Flow and Investments - Cash flows from operating activities for the 40 weeks ended December 2, 2023, were $1,045.5 million, compared to $1,202.4 million for the same period in 2022, indicating a decrease of 13.1%[9] - Net cash provided by operating activities decreased to $1,730.8 million from $2,072.0 million, reflecting a decline of 16.5%[12] - Net cash used in investing activities was $1,328.8 million, down from $1,478.7 million, indicating a reduction of 10.1%[12] - Cash and cash equivalents at the end of the period were $227.2 million, a substantial decrease from $4,420.3 million at the end of the previous year[12] Debt and Interest - Interest expense for the 12 weeks ended December 2, 2023, was $116.3 million, an increase from $84.3 million in the same period last year, reflecting a rise of 38%[9] - The fair value of total debt as of December 2, 2023, was $7,841.7 million, compared to a carrying value of $8,134.3 million, reflecting a decrease in fair value[50] - As of December 2, 2023, total debt decreased to $8,534.8 million from $8,910.1 million as of February 25, 2023, representing a reduction of approximately 4.2%[53] Taxation - The effective tax rate for the 12 weeks ended December 2, 2023, was 20.8%, down from 24.4% for the same period in 2022, primarily due to an increase in federal tax credits[29] - For the 40 weeks ended December 2, 2023, the company reported an effective tax rate of 17.9%, compared to 24.1% for the same period in 2022[30] Legal Matters - The company is involved in ongoing litigation related to the False Claims Act, with potential damages exceeding $100 million before trebling and excluding penalties[68] - The company has recorded an estimated liability for ongoing legal matters, although management believes that the aggregate estimated liabilities are reasonable[62] - The Company recorded a liability of $21.5 million for settlements related to opioid litigation in New Mexico and Nevada, which was paid by insurers in Q4 of fiscal 2022[73] Sales Performance - Pharmacy sales increased to $2,282.8 million for the 12 weeks ended December 2, 2023, compared to $1,724.4 million in the same period last year, representing a growth of 32.4%[35] - Non-perishable product sales accounted for 49.8% of total revenue for the 12 weeks ended December 2, 2023, slightly down from 51.0% in the same period last year[35] - Fresh product sales represented 30.8% of total revenue for the 12 weeks ended December 2, 2023, compared to 31.7% in the prior year[35] Merger and Acquisition Activities - The merger agreement with Kroger includes a cash consideration of $34.10 per share, reduced by a special cash dividend of $6.85 per share[38] - The company and Kroger announced a definitive agreement for the sale of select stores and distribution centers to C&S Wholesale Grocers, LLC[42] Stockholder Information - The company declared cash dividends of $0.12 per common share, totaling $69.0 million for the period[15] - The company reported a basic net income of $361.4 million for the 12 weeks ended December 2, 2023, resulting in a basic net income per Class A common share of $0.63[86] - The diluted net income per Class A common share for the 12 weeks ended December 2, 2023, was $0.62, with a net income allocated to Class A common stockholders of $361.4 million[86] Operational Metrics - The company operated 2,271 stores as of December 2, 2023, with a total retail square footage of 112.9 million[106][107] - The company has 1,726 pharmacies and 1,332 in-store branded coffee shops as of December 2, 2023[98] - Identical sales increased by 2.9% in the third quarter of fiscal 2023[104] - Digital sales surged by 21% compared to the previous year[104] Other Comprehensive Income - The ending balance of accumulated other comprehensive income (AOCI) was $68.7 million as of December 2, 2023[80] - The Company has recorded a total comprehensive income of $68.7 million for the 40 weeks ended December 2, 2023[79] Accounting and Reporting - The company is currently evaluating the impact of recently issued accounting standards on its consolidated financial statements[36][37] - Fair value measurements are categorized into a three-level hierarchy based on the transparency of inputs[44]

BOISE, Idaho--(BUSINESS WIRE)--Albertsons Companies (NYSE: ACI) today launched its 2nd Annual Albertsons Cos. Innovation Launchpad competition. After a successful event last year, the grocer is once again in search of emerging brands representing food, beverage and pet products. Independent specialty and natural food brands between $2 million and $8 million in net retail sales are encouraged to apply for the opportunity to compete live at the Natural Products Expo West in California on March 12. The award c ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 9, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-39350 Albertsons Companies, Inc. (Exact name of registrant as specified in its charter) Delaware 47-4376911 (State or other ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 17, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-39350 Albertsons Companies, Inc. (Exact name of registrant as specified in its charter) Delaware 47-4376911 (State or other jur ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended February 25, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-39350 Albertsons Companies, Inc. (Exact name of registrant as specified in its charter) Delaware 47-4376911 (State or other jurisdi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 3, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-39350 Albertsons Companies, Inc. (Exact name of registrant as specified in its charter) Delaware 47-4376911 (State or other ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 10, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-39350 Albertsons Companies, Inc. (Exact name of registrant as specified in its charter) Delaware 47-4376911 (State or othe ...

Albertsons Companies, Inc. (NYSE:ACI) Q1 2022 Earnings Conference Call July 26, 2022 8:30 AM ET Company Participants Melissa Plaisance - SVP, IR Vivek Sankaran - CEO Sharon McCollam - President and CFO Conference Call Participants John Heinbockel - Guggenheim Michael Kessler - Morgan Stanley Paul Lejuez - Citi Edward Kelly - Wells Fargo Rupesh Parikh - Oppenheimer Ken Goldman - JPMorgan Michael Montani - Evercore ISI Scott Mushkin - R5 Capital Robert Moskow - Credit Suisse Spencer Hanus - Wolfe Research Mel ...